
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AMT-116
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AMT-116 in Patients with Solid Tumors
Details : AMT-116 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 17, 2025
Lead Product(s) : AMT-116
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ADCE-T02
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Adcendo
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement
Adcendo & Multitude Announce Agreement on First-in-class ADC Targeting Tissue Factor
Details : Under this license agreement, Adcendo will obtain the exclusive development and commercialization rights of ADCE-T02 for treating non-small cell lung cancer, colorectal cancer, etc.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : ADCE-T02
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Adcendo
Deal Size : $1,000.0 million
Deal Type : Licensing Agreement

AMT-676 in Patients With Advanced Solid Tumors
Details : AMT-676 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : WuXi XDC
Deal Size : Undisclosed
Deal Type : Partnership
WuXi XDC Partners with Multitude and HySlink for ADC Discovery Technology
Details : Multitude Therapeutics will provide T-Moiety linker technologies to accelerate discovery of preclinical ADC candidates and develop novel bioconjugates for cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : WuXi XDC
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AMT-253
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AMT-253 in Patients With Advanced Solid Tumours
Details : AMT-253 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : AMT-253
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

AMT-562 in Patients With Selected Advanced Solid Tumors
Details : AMT-562 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 10, 2024

AMT-253 in Patients With Selected Advanced Solid Tumours
Details : AMT-253 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 18, 2023

AMT-116 in Patients With Advanced Solid Tumors
Details : AMT-116 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 13, 2023

AMT-151 in Patients With Selected Advanced Solid Tumours
Details : AMT-151 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CUSP06
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : OnCusp Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, OnCusp obtains the exclusive global rights to lead development and commercialization of CUSP06 worldwide outside of Greater China. CDH6 (Cadherin-6 or K-cadherin) is a high-potential ADC target for multiple solid malignancies.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
June 08, 2022
Lead Product(s) : CUSP06
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : OnCusp Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
